Suppr超能文献

评估一家联邦合格健康中心成年人中使用非苯二氮䓬类、苯二氮䓬受体激动剂类催眠药物的处方实践。

Evaluation of the prescribing practices of nonbenzodiazepine, benzodiazepine receptor agonist hypnotics in adults at a federally qualified health center.

出版信息

J Am Pharm Assoc (2003). 2019 Jul-Aug;59(4S):S146-S150. doi: 10.1016/j.japh.2019.05.006. Epub 2019 Jun 24.

Abstract

OBJECTIVE

To assess the change in prescribing of nonbenzodiazepine and benzodiazepine receptor agonist hypnotics (Z-drugs) prescribed to adults after U.S. Food and Drug Administration safety warnings.

SETTING

Five clinical sites as part of a Federally Qualified Health Center (FQHC).

PRACTICE DESCRIPTION

Virginia Garcia Memorial Health Center is an FQHC consisting of 5 patient centered medical homes.

PRACTICE INNOVATION

Examine Z-drug use in a vulnerable adult population to confirm appropriate prescribing and quality care.

EVALUATION

The primary measure was to determine the percentage of Z-drugs prescribed to patients age 18 years or older during the study period of September 1, 2016, to August 31, 2017. Patients were identified using the electronic health record. Z-drugs included zolpidem, zaleplon, and eszopiclone. Secondary measures included percentage of Z-drug prescribing to adults age 65 years and older, percentage of female patients prescribed zolpidem doses greater than 5 mg, prior behavioral health encounter, and prior pharmacotherapy for insomnia.

RESULTS

Of 22,733 adults age 18 years and older, 282 patients (1.3%) received a Z-drug prescription during the study period. Forty-nine (28.9%) female patients received 10 mg of zolpidem nightly, a zolpidem dose higher than the recommended 5 mg nightly. In addition, of 2239 patients age 65 years and older, 34 patients (1.5%) received a prescription for a Z-drug.

CONCLUSION

Prescribing rates of zolpidem in 10-mg doses to female patients were high, indicating that providers could benefit from further education on this topic. In the population, and in adults age 65 years and older, Z-drug prescribing in an FQHC was low compared with available prescribing rates.

摘要

目的

评估美国食品和药物管理局安全警告后,非苯二氮䓬类和苯二氮䓬受体激动剂催眠药(Z 类药物)在成年人中的处方变化。

背景

作为联邦合格健康中心(FQHC)的五个临床站点之一。

实践创新

检查脆弱成年人群中 Z 类药物的使用情况,以确认适当的处方和高质量的护理。

评估

主要措施是确定在 2016 年 9 月 1 日至 2017 年 8 月 31 日期间,年龄在 18 岁及以上的患者开具 Z 类药物的比例。患者通过电子健康记录确定。Z 类药物包括唑吡坦、扎来普隆和右佐匹克隆。次要措施包括年龄在 65 岁及以上的成年人开具 Z 类药物的比例、开具大于 5 毫克唑吡坦剂量的女性患者的比例、之前的行为健康就诊和失眠的先前药物治疗。

结果

在 22733 名 18 岁及以上的成年人中,有 282 名患者(1.3%)在研究期间开具了 Z 类药物处方。49 名(28.9%)女性患者每晚服用 10 毫克唑吡坦,剂量高于推荐的每晚 5 毫克。此外,在 2239 名年龄在 65 岁及以上的患者中,有 34 名患者(1.5%)开具了 Z 类药物处方。

结论

女性患者服用 10 毫克唑吡坦的处方率很高,表明提供者可能受益于这一主题的进一步教育。在该人群中,以及在年龄在 65 岁及以上的成年人中,FQHC 中 Z 类药物的处方率与可用处方率相比较低。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验